Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company specializing in novel products for rare and ultrarare genetic diseases, has announced a conference call scheduled for August 1, 2024, at 5:00 p.m. ET. The call will cover the company's financial results and corporate update for the second quarter of 2024, ending June 30. Investors and interested parties can access the live webcast and replay through the company's investor relations website. The replay will remain available for three months following the call, providing extended access to the information presented.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), un'azienda biopharmaceutical specializzata in prodotti innovativi per malattie genetiche rare e ultrarare, ha annunciato una conferenza telefonica programmata per il 1 agosto 2024, alle 17:00 ET. La chiamata tratterà i risultati finanziari e l'aggiornamento aziendale per il secondo trimestre del 2024, che si conclude il 30 giugno. Gli investitori e i soggetti interessati possono accedere alla diretta webcast e alla riproduzione tramite il sito web delle relazioni con gli investitori dell'azienda. La riproduzione rimarrà disponibile per tre mesi dopo la chiamata, offrendo così un accesso prolungato alle informazioni presentate.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), una compañía biofarmacéutica especializada en productos novedosos para enfermedades genéticas raras y ultrarraras, ha anunciado una conferencia telefónica programada para el 1 de agosto de 2024, a las 5:00 p.m. ET. La llamada cubrirá los resultados financieros y la actualización corporativa para el segundo trimestre de 2024, que finaliza el 30 de junio. Los inversores y las partes interesadas pueden acceder a la transmisión en vivo y a la repetición a través del sitio web de relaciones con inversores de la compañía. La repetición estará disponible durante tres meses después de la llamada, proporcionando acceso extendido a la información presentada.
울트라제닉스 제약 주식회사 (NASDAQ: RARE)은 희귀 및 초희귀 유전 질환을 위한 혁신 제품을 전문으로 하는 생명공학 회사로, 2024년 8월 1일 오후 5시 ET에 예정된 전화 회의를 발표했습니다. 이번 통화는 2024년 2분기 재무 결과 및 기업 업데이트를 다룰 예정이며, 6월 30일로 종료됩니다. 투자자 및 관심 있는 당사자들은 회사의 투자자 관계 웹사이트를 통해 생중계 및 다시 보기를 이용할 수 있습니다. 다시 보기는 통화 후 3개월 동안 이용 가능하여, 제공된 정보에 대한 연장된 접근을 제공합니다.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), une entreprise biopharmaceutique spécialisée dans des produits novateurs pour des maladies génétiques rares et ultraraires, a annoncé une conférence téléphonique prévue pour le 1er août 2024 à 17h00 ET. L'appel couvrira les résultats financiers et la mise à jour de l'entreprise pour le deuxième trimestre de 2024, se terminant le 30 juin. Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct et à la rediffusion via le site web des relations avec les investisseurs de l'entreprise. La rediffusion restera disponible pendant trois mois après l'appel, offrant ainsi un accès prolongé aux informations présentées.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf neuartige Produkte für seltene und ultrarare genetische Krankheiten spezialisiert hat, hat eine Telefonkonferenz für den 1. August 2024, um 17:00 Uhr ET angekündigt. Die Konferenz wird die Finanzresultate und Unternehmensaktualisierungen für das zweite Quartal 2024, das am 30. Juni endet, behandeln. Investoren und Interessierte können auf die Live-Webcast und die Aufzeichnung über die Investor-Relations-Website des Unternehmens zugreifen. Die Aufzeichnung wird für drei Monate nach der Konferenz verfügbar sein und so einen erweiterten Zugang zu den präsentierten Informationen bieten.
- None.
- None.
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, August 1, 2024, to discuss its financial results and corporate update for the quarter ending June 30, 2024.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors
Joshua Higa
(415) 475-6370
Media
Carolyn Wang
(415) 225-5050
FAQ
When is Ultragenyx (RARE) hosting its Q2 2024 earnings call?
Where can I access Ultragenyx's (RARE) Q2 2024 earnings call?
How long will the replay of Ultragenyx's (RARE) Q2 2024 earnings call be available?
What period does Ultragenyx's (RARE) Q2 2024 financial results cover?
